Success Metrics

Clinical Success Rate
50.0%

Based on 5 completed trials

Completion Rate
50%(5/10)
Active Trials
0(0%)
Results Posted
160%(8 trials)
Terminated
5(50%)

Phase Distribution

Ph phase_1
2
20%
Ph phase_4
1
10%
Ph phase_2
3
30%
Ph phase_3
3
30%
Ph not_applicable
1
10%

Phase Distribution

2

Early Stage

3

Mid Stage

4

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
2(20.0%)
Phase 2Efficacy & side effects
3(30.0%)
Phase 3Large-scale testing
3(30.0%)
Phase 4Post-market surveillance
1(10.0%)
N/ANon-phased studies
1(10.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

50.0%

5 of 10 finished

Non-Completion Rate

50.0%

5 ended early

Currently Active

0

trials recruiting

Total Trials

10

all time

Status Distribution
Completed(5)
Terminated(5)

Detailed Status

Terminated5
Completed5

Development Timeline

Analytics

Development Status

Total Trials
10
Active
0
Success Rate
50.0%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (20.0%)
Phase 23 (30.0%)
Phase 33 (30.0%)
Phase 41 (10.0%)
N/A1 (10.0%)

Trials by Status

terminated550%
completed550%

Recent Activity

0 active trials
Showing 5 of 10
completedphase_3

Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy

NCT03578081
completedphase_4

Safety of a Three-Day Fosaprepitant Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-045)

NCT04054193
terminatedphase_2

Rolapitant Hydrochloride in Preventing Nausea/Vomiting in Patients With Sarcoma Receiving Chemotherapy

NCT02732015
completednot_applicable

Fosaprepitant Dimeglumine in Preventing Nausea and Vomiting in Patients With Gastrointestinal Cancer Receiving Combination Chemotherapy

NCT01504711
completedphase_3

Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031)

NCT01594749
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT03578081Phase 3

Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy

Completed
NCT04054193Phase 4

Safety of a Three-Day Fosaprepitant Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-045)

Completed
NCT02732015Phase 2

Rolapitant Hydrochloride in Preventing Nausea/Vomiting in Patients With Sarcoma Receiving Chemotherapy

Terminated
NCT01504711Not Applicable

Fosaprepitant Dimeglumine in Preventing Nausea and Vomiting in Patients With Gastrointestinal Cancer Receiving Combination Chemotherapy

Completed
NCT01594749Phase 3

Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031)

Completed
NCT01405924Phase 2

Fosaprepitant (MK-0517, EMEND® IV) In Salvage Treatment of Chemotherapy-Induced Vomiting (MK-0517-030)

Terminated
NCT01649258Phase 1

Fosaprepitant Dimeglumine and Granisetron Transdermal System in Preventing Nausea and Vomiting in Patients With Breast Cancer Undergoing Chemotherapy

Terminated
NCT00895245Phase 2

Fosaprepitant Dimeglumine, Palonosetron Hydrochloride, and Dexamethasone in Preventing Nausea and Vomiting Caused by Cisplatin in Patients With Stage III or Stage IV Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy

Terminated
NCT01031953Phase 1

Fosaprepitant Dimeglumine in Treating Patients With Nausea and Vomiting Caused By Chemotherapy

Terminated
NCT01074697Phase 3

Efficacy of Two Antiemetic Regimens in Patients Receiving Radiotherapy and Concomitant Weekly Cisplatin

Completed

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10